Russian vaccine Sputnik V has been approved for emergency use in India by an expert panel of India's central drug authority. Sputnik V is the third COVID-19 vaccine approved by the Subject Expert Committee (SEC) after Covishield and Covaxin. It was developed by Russia's Gamaleya Research Institute of Epidemiology and Microbiology.
The Russian jab has an efficacy rate of 91.6% and is carrying out its phase-3 clinical trials in Belarus, UAE, India, and Venezuela, according to Sputnik-V's website. The Russian Direct Investment Fund (RDIF) joined hands with Dr Reddy's in September 2020 to carry out clinical trials of Sputnik V in India.
The RDIF has also signed agreements for the manufacture of vaccine doses with several Indian pharmaceutical firms, including Gland Pharma, Hetero Biopharma, Virchow Biotech, and Stelis Biopharma.